### SUMMARY SHEET

<table>
<thead>
<tr>
<th>Agenda Nr. 2.07- 12.0</th>
<th>Subject</th>
<th>TB Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>For Information □</td>
<td>For Discussion □</td>
<td>For Decision □</td>
</tr>
</tbody>
</table>

#### Rationale
The Coordinating Board discussed the Research Movement at its 12th Meeting (18-19 April 2007, Geneva) and advised further consultation among interested stakeholders and clarification of Partnership and WHO roles. In addition to consultation with individual stakeholders, the WHO Strategic and Technical Advisory Group on TB (STAG) meeting (11-13 June, 2007, Geneva) provided an opportunity for key partners to provide input to the process of consultation in developing the Research Movement under the auspices of the Partnership. STAG requested its Chair, as a Permanent Member of the Coordinating Board, report to the next Board meeting on STAG’s conclusions and recommendations following review of WHO’s role in, and contribution to, the Research Movement.

#### Summary
STAG fully supports the Research Movement in accelerating progress towards the global elimination of TB by 2050. STAG endorsed the activities proposed (see STAG background document) in line with the following objectives:

1. To provide leadership and advocacy to mobilize increased resources in support of a coherent and comprehensive global TB research agenda; and
2. To provide a forum for TB research stakeholders (including funders and implementers) to coordinate plans and actions, with the result of ensuring that research needs are addressed, opportunities prioritized and gaps filled.

STAG welcomes WHO’s leadership role in the development of the Research Movement under the auspices of the Partnership, and the close collaboration between WHO and the Partnership. STAG recognizes the relative advantages of WHO’s contribution e.g.:

- Its links with countries and representation of country needs;
- Policy mandate and associated opportunities to identify research needs;
- Role in technical collaboration;
- Lead role in global TB M&E; and
- Institutional commitment to promote research.

And the relative advantages of the Partnership, e.g.:

- Promoting the development of a wide range of technologies through the new tools Working Groups;
- Convening a wide range of stakeholders;
- Intensifying engagement with research funders; and
- Advocacy and community mobilization for TB research through the ACSM Working Group.

#### Decisions requested (from the Stop TB Coordinating Board)
1. Endorsement of the relative roles of the Partnership and WHO.
2. Endorsement of the proposed plan of action which is, for the moment, based on STAG’s endorsement and calls for full ownership by all partners.

#### Implications (political/financial/staffing etc):
Full-time staff needed in TBP.

#### Next Steps

**Action Required:** Research Movement 1) launched at Bellagio conference (or similar); and 2) featured at Global Ministerial Forum on Health Research, Bamako, 2008.

**Focal Point:** Research Movement coordinator in Partnership secretariat.

**Timeframe:** Launch in first quarter of 2008; Bamako Forum 17-20 November 2008.

---

13th Stop TB Partnership Coordinating Board Meeting  
23-24 October 2007 - Berlin, Germany